Impaired renal function and associated risk factors in newly diagnosed HIV-infected adults in Gulu Hospital, Northern Uganda

BMC Nephrology

Pauline Byakika-Kibwika¹  Paska Apiyo²  James Henry Obol³  Ronald Wanyama³  Pancras Odongo³ 

[1] Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda;Infectious Diseases Clinic, Gulu Regional Referral Hospital, Gulu, Uganda;Faculty of Medicine, Gulu University, Gulu, Uganda

关键词: Northern Uganda;    Gulu;    HIV;    Kidney disease;    Renal function;   

Others  :  1145778
DOI  :  10.1186/s12882-015-0035-3

 received in 2014-10-16, accepted in 2015-03-18,  发布年份 2015

【 摘 要 】

Background

Screening for renal diseases should be performed at the time of diagnosis of human immunodeficiency virus (HIV) infection. Despite the high prevalence of HIV/AIDS in Northern Uganda, little is known about the status of renal function and its correlates in the newly diagnosed HIV-infected individuals in this resource limited region. We aimed to determine the status of renal function and factors associated with impaired renal function in newly diagnosed HIV-infected adults in Northern Uganda.

Methods

This was a seven month cross-sectional hospital-based study, involving newly diagnosed HIV-infected patients, 18 years and older. Patients with history of diabetes mellitus, hypertension and renal disease were excluded. Estimated glomerular filtration rate (eGFR) was calculated using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula (Table one). Factors associated with impaired renal function (eGFR < 60 ml/min/1.73 m²) were thus sought.

Results

We enrolled 361 participants (230, 63.7% female) with Mean ± standard deviation age of 31.4 ± 9.5 years. 52, (14.4%) had impaired renal function (eGFR <60 mL/min/1.73 m²) and of this 37 (71.2%) moderate renal impairment (eGFR 30–59.9 mL/min/1.73 m²) while 15 (28.8%) had severe renal impairment (eGFR <30 mL/min/1.73 m²). Proteinuria was recorded in 189 (52.4%) participants. Of these, 154 (81.5%) had mild (1+) while 8 (4.2%) had severe (3+) proteinuria. Using logistic regression, age, CD4 cell count, and proteinuria were significantly associated with impaired renal function; age >34 years (OR 2.8, 95% CI 1.3 – 5.9; P =0.009), CD4 count <350 cells/μL (OR 2.4, 95% CI 1.0-4.7; P =0.039) and proteinuria (OR 9.6, 95% CI 5.2–17.9; P < 0.001).

Conclusion

The prevalence of impaired renal function was high in new HIV-infected individuals in this region with limited resources. So, screening for renal disease in HIV is recommended at the time of HIV diagnosis.

【 授权许可】

   
2015 Odongo et al.; licensee BioMed Central.

【 参考文献 】

• [1]Kalyesubula R, Perazella MA: Nephrotoxicity of HAART. AIDS Res Treat 2011, 2011:562790.
• [2]Crowley S, Rigsby M: The spectrum of HIV-associated renal disease. AIDS Clin Care 1996, 8(7):53-6.
• [3]Arendse CG, Wearne N, Okpechi IG, Swanepoel CR: The acute, the chronic and the news of HIV-related renal disease in Africa. Kidney Int 2010, 78(3):239-45.
• [4]Connolly JO, Weston CE, Hendry BM: HIV-associated renal disease in London hospitals. QJM 1995, 88(9):627-34.
• [5]Calza L, Vanino E, Magistrelli E, Salvadori C, Cascavilla A, Colangeli V, et al.: Prevalence of renal disease within an urban HIV-infected cohort in northern Italy. Clin Exp Nephrol 2014, 18(1):104-12.
• [6]Ekat MH, Courpotin C, Diafouka M, Akolbout M, Mahambou-Nsonde D, Bitsindou PR, et al.: [Prevalence and factors associated with renal disease among patients with newly diagnoses of HIV in Brazzaville, Republic of Congo]. Med et sante tropicales 2013, 23(2):176-80. Epub 2013/06/22. Prevalence et facteurs associes a l'insuffisance renale chez les patients nouvellement depistes VIH-positifs a Brazzaville (Republique du Congo)
• [7]Gupta V, Gupta S, Sinha S, Sharma SK, Dinda AK, Agarwal SK, et al.: HIV associated renal disease: a pilot study from north India. Indian J Med Res 2013, 137(5):950-6.
• [8]Emem CP, Arogundade F, Sanusi A, Adelusola K, Wokoma F, Akinsola A: Renal disease in HIV-seropositive patients in Nigeria: an assessment of prevalence, clinical features and risk factors. Eur Renal Assoc 2008, 23(2):741-6.
• [9]Fine DM: Renal disease and toxicities: issues for HIV care providers. Topics HIV Med 2006, 14(5):164-9.
• [10]Szczech LA, Hoover DR, Feldman JG, Cohen MH, Gange SJ, Gooze L, et al.: Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy. Clin Infec Dis 2004, 39(8):1199-206.
• [11]Szczech LA: Renal disease: the effects of HIV and antiretroviral therapy and the implications for early antiretroviral therapy initiation. Curr Opin HIV AIDS 2009, 4(3):167-70.
• [12]Bohmart A, Burns G: Renal disease in an urban HIV population in the era prior and following the introduction of highly active antiretroviral therapy. J Natl Med Assoc 2011, 103(6):513-7.
• [13]Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al.: A new equation to estimate glomerular filtration rate. Ann Intern Med 2009, 150(9):604-12.
• [14]National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification Am J Kidney Dis 2002, 39(39(2 suppl 1)):S1-266.
• [15]Franey C, Knott D, Barnighausen T, Dedicoat M, Adam A, Lessells RJ, et al.: Renal impairment in a rural African antiretroviral programme. BMC Infect Dis 2009, 9:143. BioMed Central Full Text
• [16]Simerville JA, Maxted WC, Pahira JJ: Urinalysis: a comprehensive review. Am Fam Physician 2005, 71:1153-62.
• [17]Mulenga LB, Kruse G, Lakhi S, Cantrell RA, Reid SE, Zulu I, et al.: Baseline renal insufficiency and risk of death among HIV-infected adults on antiretroviral therapy in Lusaka, Zambia. AIDS 2008, 22:1821-7.
• [18]Onodugo OD, Chukwuka C, Onyedum C, Ejim E, Mbah A, Nkwo P, et al.: Baseline Renal Function among Antiretroviral Therapy-Naive, HIV-Infected Patients in South East Nigeria. J Int Assoc Providers AIDS Care 2013, 00:1-5.
• [19]Kaloustian KW, Gupta SK, Muloma E, Owino-Ong’or W, Sidle J, Aubrey RW, et al.: Renal disease in an antiretroviral-naı¨ve HIV-infected outpatient population in Western Kenya. Nephrol Dial Transplant 2007, 22:2208-12.
• [20]Wyatt CM, Shi Q, Novak JE, Hoover DR, Szczech L, Mugabo JS, et al.: Prevalence of Kidney Disease in HIV-Infected and Uninfected Rwandan Women. PLoS One 2011, 6(3):e18352. Doi 10.1371/journal.pone.0018352
• [21]Ekat E, Diafouka D: Renal dysfunction and factors associated among newly identified HIV-infected patients in Brazzaville, Republic of Congo. J Int AIDS Soc 2012, 15(Suppl 4):18313.
• [22]Zachariah R, Fitzgerald M, Massaquoi M, Pasulani O, Arnould L, Makombe S, et al.: Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi. AIDS 2006, 20(18):2355-60.
• [23]Struik GM, den Exter RA, Munthali C, Chipeta D, Van Oosterhout JJ, Nouwen JL, et al.: The prevalence of renal impairment among adults with early HIV disease in Blantyre, Malawi. Int J STD AIDS 2011, 22:457-62.
• [24]Janakiraman H, Abraham G, Matthew M, Kuruvilla S, Panikar V, Solomon S, et al.: Correlation of CD4 Counts with Renal Disease in HIV Positive Patients. Saudi J Kidney Dis Transpl 2008, 19:603-7.
• [25]Chioma PE, Arogundade F, Sanusi A, Kayode A, Wokoma F, Akinsola A: Renal disease in HIV-seropositive patients in Nigeria: an assessment of prevalence, clinical features and risk factors. Nephrol Dial Transplant 2008, 23:741-6.
• [26]Longo AL, Lepira FB, Sumaili EK, Makulo JRR, Mukumbi H, Bukabau JB, et al.: Prevalence of Low Estimated Glomerular Filtration Rate, Proteinuria, and Associated Risk Factors Among HIV-Infected Black Patients Using Cockroft–Gault and Modification of Diet in Renal Disease Study Equations. J Acquir Immune Defic Syndr 2012, 59(1):59-64.
• [27]Peters PJ, Moore D, Mermin J, Brooks JT, Downing R, Were W, et al.: Renal function improves among Ugandans on NNRTI-based HAART: 24 month follow-up from the Home-Based AIDS Care (HBAC) program in rural Uganda. Conference on Retroviruses and Opportunistic Infections, Los Angeles; 2007.
• [28]Fabian J, Naicker S: HIV and kidney disease in sub-Saharan Africa. Nat Rev Nephrol 2009, 5(10):591-8.
• [29]Reid A, Stohr W, Walker AS, Williams IG, Kityo C, Hughes P, et al.: Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy. Clin Infect Dis 2008, 46:1271-81.
• [30]Szczech LA, Gupta SK, Habash R, Guasch A, Kalayjian R, Appel R, et al.: The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney Int 2004, 66(3):1145-52.
• [31]Mauss S, Berger F, Schmutz G: Antiretroviral therapy with tenofovir is associated with mild renal dysfunction. AIDS 2005, 19(1):93-5.
• [32]Julg BD, Bogner JR, Crispin A, Goebel FD: Progression of renal impairment under therapy with tenofovir. AIDS 2005, 19:1332-3.